Abstract 1646
Background
Cervical cancer ranks first among gynecologic malignancies. Neoadjuvant chemotherapy combined with surgery is currently a recommended treatment for locally advanced cervical cancer, however the patient's prognosis is still poor and easy to recur even if the chemotherapy works significantly. We need more effective assessment method for local advanced cervical cancer. Therefore, we evaluated relationship between chemotherapeutic effect and prognosis on the expression of immunological biomarkers including CD4+, CD8+ and Foxp3 pre- and post-neoadjuvant chemotherapy for locally advanced cervical cancer.
Methods
CD4+, CD8+ and Foxp3 expression by IHC in 45 cases of locally advanced (IB2-IIB) cervical cancer pre- and post-neoadjuvant chemotherapy, computer software was used to quantitatively analyzed. The relationship between IHC results and clinicopathological characteristics, chemotherapy efficacy, PFS and OS was analyzed by SPSS software.
Results
The expression of CD4, CD8 and Foxp3 in locally advanced cervical cancer before and after neoadjuvant chemotherapy was not related to patients’ age and size of tumor (P > 0.05), which was related to FIGO staging and histological grade. The expression of CD4 and CD8 increased significantly after chemotherapy (P = 0.016, P = 0.009), while the expression of FoxP3 decreased significantly (P = 0.002). There was a significant correlation between the expression of CD8 (P = 0.005), Foxp3 (P = 0.041) and PFS in locally advanced cervical cancer, while CD4 had no significant correlation (P = 0.581). However, there is no significant correlation between OS and CD4 (P = 0.686), CD8 (P = 0.858) and Foxp3 (P = 0.689).
Conclusions
CD4, CD8 and Foxp3 are associated with tumor staging and pathological grading in neoadjuvant chemotherapy for locally advanced cervical cancer, and the expression change of CD8 and Foxp3 before and after chemotherapy can be used as an independent prognostic indicator.
Clinical trial identification
Legal entity responsible for the study
Wen Di.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract